RPS18P6

Across TCGA pan-cancer cohorts, RPS18P6 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPS18P6 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPS18P6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS18P6 expression acts as an unfavorable survival marker.

LUAD and SKCM are the cancer types where RPS18P6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
SKCM	OS	Median	All	0.179	0.781	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RPS18P6–LUAD (OS)

Open the LUAD breakdown →